Management of pulmonary arterial hypertension in the neonatal unit

Cardiology in Review

Volumn 18, Issue 2, 2010, Pages 73-75

  Krishnan, Usha ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Bosentan; Chronic lung disease of infancy; Persistent pulmonary hypertension in the newborn; Pulmonary hypertension; Sildenafil

Indexed keywords

BOSENTAN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN DERIVATIVE; SILDENAFIL;

ANTIHYPERTENSIVE THERAPY; CHRONIC LUNG DISEASE; CLINICAL FEATURE; DOPPLER ECHOCARDIOGRAPHY; DRUG POTENTIATION; EXTRACORPOREAL OXYGENATION; HEART CATHETERIZATION; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; LUNG ANGIOGRAPHY; LUNG BIOPSY; LUNG DYSPLASIA; LUNG VASCULAR RESISTANCE; NEWBORN CARE; NEWBORN DISEASE; PATHOPHYSIOLOGY; PERSISTENT PULMONARY HYPERTENSION; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION;

AGE FACTORS; ANTIHYPERTENSIVE AGENTS; ENDOTHELIUM-DEPENDENT RELAXING FACTORS; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; INFANT, NEWBORN; NITRIC OXIDE; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PROGNOSIS; PURINES; RECEPTORS, ENDOTHELIN; SULFONES;

EID: 77149156961     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e3181ce9edb     Document Type: Review

References (18)

1. Abman SH. Recent advances in the pathogenesis and treatment of persistent pulmonary hypertension of the newborn. Neonatology. 2007;91:283-290.
2. Krishnan U, Krishnan S, Gewitz M. Treatment of pulmonary hypertension in children with chronic lung disease with newer oral therapies. Pediatr Cardiol. 2008;29:1082-1086.
3. Abman SH. Monitoring cardiovascular function in infants with chronic lung disease of prematurity. Arch Dis Child Fetal Neonatal Ed. 2002;87:F15-F18.
4. Konduri GG, Kim UO. Advances in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatr Clin North Am. 2009;56:579-600.
5. Hoskote AU, Castle RA, Hoo AF, et al. Airway function in infants treated with inhaled nitric oxide for persistent pulmonary hypertension. Pediatr Pulmonol. 2008;43:224-235.
6. Haworth SG. Pulmonary endothelium in the perinatal period. Pharmacol Rep. 2006;58(suppl):153-164.
7. Mathew R, Huang J, Gewitz MH. Pulmonary artery hypertension: caveolin-1 and eNOS interrelationship: a new perspective. Cardiol Rev. 2007;15:143-149.
8. Nadeau S, Baribeau J, Janvier A, et al. Changes in expression of vascular endothelial growth factor and its receptors in neonatal hypoxia-induced pulmonary hypertension. Pediatr Res. 2005;58:199-205.
9. Farrow KN, Fliman P, Steinhorn RH. The diseases treated with ECMO: focus on PPHN. Semin Perinatol. 2005;29:8-14.
10. Stenmark KR, Abman SH. Lung vascular development: implications for the pathogenesis of bronchopulmonary dysplasia. Annu Rev Physiol. 2005;67: 623-661.
11. Mourani PM, Sontag MK, Younoszai A, et al. Clinical utility of echocardiography for the diagnosis and management of pulmonary vascular disease in young children with chronic lung disease. Pediatrics. 2008;121:317-325.
12. Humbert M. Update in pulmonary hypertension 2008. Am J Respir Crit Care Med. 2009;179:650-656.
13. Somaschini M, Bellan C, Chinaglia D, et al. Congenital misalignment of pulmonary vessels and alveolar capillary dysplasia: how to manage a neonatal irreversible lung disease? J Perinatol. 2000;20:189-192.
14. Walsh-Sukys MC, Tyson JE, Wright LL, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics. 2000;105:14-20.
15. Ladha F, Bonnet S, Eaton F, et al. Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury. Am J Respir Crit Care Med. 2005;172:750-756.
16. de Visser YP, Walther FJ, Laghmani el H, et al. Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury. Respir Res. 2009;10:30.
17. Madden BP, Allenby M, Loke TK, et al. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vasc Pharmacol. 2006;44:372-376.
18. Wilkins MR, Paul GA, Strange JW. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. Am J Resp Crit Care Med. 2005;171:1292-1297.